Cargando…
1548. Risk of Severe Herpes Zoster (HZ) in Allogeneic Hematopoietic-Cell Transplantation (HCT) Recipients
BACKGROUND: Allogeneic-HCT recipients are at increased risk for varicella zoster virus (VZV) reactivation and associated complications. Prevalence, timing, and risk factors for severe HZ are uncertain in the era of acyclovir (ACV) prophylaxis. Identification of patients at risk for severe HZ can hel...
Autores principales: | Baumrin, Emily, Cheng, Matthew P, Kanjilal, Sanjat, Issa, Nicolas, Baden, Lindsey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253630/ http://dx.doi.org/10.1093/ofid/ofy210.1376 |
Ejemplares similares
-
36. Safety and Reactogenicity of the Adjuvanted Recombinant Zoster Vaccine after Allogeneic Hematopoietic Stem Cell Transplantation
por: Baumrin, Emily, et al.
Publicado: (2020) -
1557. Acyclovir-Resistant (ACV-R) Herpes Simplex Virus (HSV) Disease in Patients with Hematologic Malignancies (HM) and Hematopoietic-Cell Transplant (HCT) Recipients
por: Pandit, Alisha, et al.
Publicado: (2018) -
100. Safety Analysis of Live-Attenuated Measles, Mumps, Rubella Vaccine Among Hematopoietic Cell Transplant Recipients Vaccinated Within Two Years of Transplant
por: Mitre, Xhoi, et al.
Publicado: (2021) -
1753. Adherence and Immunogenicity of Early Vaccination in Pediatric Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Recipients
por: Danino, Dana, et al.
Publicado: (2019) -
Safety of Live-Attenuated Measles, Mumps, and Rubella Vaccine Administered Within 2 Years of Hematopoietic Cell Transplant
por: Desjardins, Michaël, et al.
Publicado: (2021)